This website is intended for UK healthcare professionals only and contains promotional content.

Report an adverse event here
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE:Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on the following pages, including but not limited to these Established Medicines. For more information please click here.​

INFORMATION FOR MEMBERS OF THE GENERAL PUBLIC, PATIENTS AND CAREGIVERS

Our Products

Adverse events should be reported: If, as a patient, you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. By reporting side effects you can help provide more information on the safety of this medicine. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard/. Adverse events should also be reported to Grünenthal Ltd. at drugsafety.uk@grunenthal.com

Abstral® (fentanyl citrate)

PATIENT INFORMATION LEAFLET
RISK MATERIAL

MOVENTIG® (naloxegol)

PATIENT INFORMATION LEAFLET

PecFent® (fentanyl citrate) nasal spray

PATIENT INFORMATION LEAFLET
RISK MATERIAL

RECTOGESIC® (glyceryl trinitrate) rectal ointment

PATIENT INFORMATION LEAFLET

SANCUSO® (granisetron) transdermal patch

PATIENT INFORMATION LEAFLET

STEXEROL-D3® (colecalciferol)

PATIENT INFORMATION LEAFLET

Average:

This website is for healthcare professionals only.

If you are a registered healthcare professional outside the UK please visit the Grünenthal Meds Website

M-GRM-HQ-11-24-0006 May 2025